Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Turnstone Biologics Corp.

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers ANNX ARWR PTGX TSBX
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics to Participate in Upcoming Investor Conferences
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
From Turnstone Biologics Corp.
Via GlobeNewswire
Tickers TSBX
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Announces TIL Therapy Research Collaboration with the University of Montreal Hospital Research Centre
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Announces Executive Leadership Appointments
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Expands Scientific Advisory Board with Appointments of Dr. James Mulé and Dr. Eric Tran
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Raises $80 Million Series D Financing
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Appoints Stewart Abbot, Ph.D., as Chief Scientific Officer
From Turnstone Biologics Corp.
Via Business Wire
Turnstone Biologics Announces Executive Leadership Promotions and Board Appointment
From Turnstone Biologics Corp.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.